Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Drugs

Results: 51-75/1748

Authors: Cheer, SM Noble, S
Citation: Sm. Cheer et S. Noble, Zoledronic acid, DRUGS, 61(6), 2001, pp. 799-805

Authors: Lipton, A
Citation: A. Lipton, Zoledronic acid, DRUGS, 61(6), 2001, pp. 806-806

Authors: Body, JJ
Citation: Jj. Body, Zoledronic acid, DRUGS, 61(6), 2001, pp. 806-806

Authors: Curran, M Wiseman, L
Citation: M. Curran et L. Wiseman, Fulvestrant, DRUGS, 61(6), 2001, pp. 807-813

Authors: Blamey, RW
Citation: Rw. Blamey, Fulvestrant, DRUGS, 61(6), 2001, pp. 814-814

Authors: Carlson, RW
Citation: Rw. Carlson, Fulvestrant, DRUGS, 61(6), 2001, pp. 814-814

Authors: Balfour, JAB Figgitt, DP
Citation: Jab. Balfour et Dp. Figgitt, Telithromycin, DRUGS, 61(6), 2001, pp. 815-829

Authors: Barry, AL
Citation: Al. Barry, Telithromycin, DRUGS, 61(6), 2001, pp. 830-831

Authors: Norrby, SR
Citation: Sr. Norrby, Telithromycin, DRUGS, 61(6), 2001, pp. 830-830

Authors: Matheson, AJ Figgitt, DP
Citation: Aj. Matheson et Dp. Figgitt, Rofecoxib - A review of its use in the management of osteoarthritis, acutepain and rheumatoid arthritis, DRUGS, 61(6), 2001, pp. 833-865

Authors: Hurst, M Jarvis, B
Citation: M. Hurst et B. Jarvis, Perindopril - An updated review of its use in hypertension, DRUGS, 61(6), 2001, pp. 867-896

Authors: Sader, HS Gales, AC
Citation: Hs. Sader et Ac. Gales, Emerging strategies in infectious diseases - New carbapenem and trinem antibacterial agents, DRUGS, 61(5), 2001, pp. 553-564

Authors: van't Veen, AJ
Citation: Aj. Van'T Veen, Vaccines without thiomersal - Why so necessary, why so long coming?, DRUGS, 61(5), 2001, pp. 565-572

Authors: Badia, L Lund, V
Citation: L. Badia et V. Lund, Topical corticosteroids in nasal polyposis, DRUGS, 61(5), 2001, pp. 573-578

Authors: Storr, M Allescher, HD Classen, M
Citation: M. Storr et al., Current concepts on pathophysiology, diagnosis and treatment of diffuse oesophageal spasm, DRUGS, 61(5), 2001, pp. 579-591

Authors: Hamblin, TJ
Citation: Tj. Hamblin, Achieving optimal outcomes in chronic lymphocytic leukaemia, DRUGS, 61(5), 2001, pp. 593-611

Authors: Figgitt, DP Gillies, PS Goa, KL
Citation: Dp. Figgitt et al., Levosimendan, DRUGS, 61(5), 2001, pp. 613-627

Authors: Nieminen, MS
Citation: Ms. Nieminen, Levosimendan - A viewpoint, DRUGS, 61(5), 2001, pp. 628-629

Authors: Aronow, WS
Citation: Ws. Aronow, Levosimendan - A viewpoint, DRUGS, 61(5), 2001, pp. 628-628

Authors: Balfour, JAB Goa, KL
Citation: Jab. Balfour et Kl. Goa, Bendamustine, DRUGS, 61(5), 2001, pp. 631-638

Authors: Schoffski, P Ganser, A
Citation: P. Schoffski et A. Ganser, Bendamustine - A viewpoint, DRUGS, 61(5), 2001, pp. 639-639

Authors: Herold, M
Citation: M. Herold, Bendamustine - A viewpoint, DRUGS, 61(5), 2001, pp. 640-640

Authors: Culy, CR Spencer, CM
Citation: Cr. Culy et Cm. Spencer, Amifostine - An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome, DRUGS, 61(5), 2001, pp. 641-684

Authors: Dunn, CJ Goa, KL
Citation: Cj. Dunn et Kl. Goa, Risedronate - A review of its pharmacological properties and clinical use in resorptive bone disease, DRUGS, 61(5), 2001, pp. 685-712

Authors: Dunne, F Kendall, MJ Martin, U
Citation: F. Dunne et al., beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus - Is there a role?, DRUGS, 61(4), 2001, pp. 429-435
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>